Ayrton Capital’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Ayrton Capital’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-28,393	Closed	-$505	–	99
2022 Q4	$505	Hold	28,393	–	–	﹤0.01%	94
2022 Q3	$2K	Hold	28,393	–	–	﹤0.01%	114
2022 Q2	$2K	Hold	28,393	–	–	﹤0.01%	117
2022 Q1	$6K	Hold	28,393	–	–	0.01%	120
2021 Q4	$15K	Buy	+28,393	New	+$16.1K	0.01%	113

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Ayrton Capital's IBER.WS Position: Q1 2023 in Review

Ayrton Capital sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 28,393 shares — an estimated $505 sold.

Ayrton Capital first reported a position in IBER.WS in Q4 2021 and held it in 5 quarters. The position peaked at $15K in Q4 2021. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Ayrton Capital reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Ayrton Capital sold 28,393 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $505.
Ayrton Capital first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q4 2021 and held it in 5 quarters.
Ayrton Capital's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $15K in Q4 2021.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Ayrton Capital's 13F filing for Q1 2023, filed 12 May 2023.